Health Sciences North Research Institute | Sudbury, Canada logo

Health Sciences North Research Institute | Sudbury, Canada

Research site
Location
41 Ramsey Lake Road, Sudbury, Ontario, Canada
Site insights

Top conditions

Breast Cancer (6 trials)

Lung Cancer (6 trials)

Carcinoma (5 trials)

Non-Small-Cell Lung Carcinoma (5 trials)

Atrial Fibrillation (4 trials)

Top treatments

Durvalumab
Pembrolizumab
Exemestane
Bevacizumab
Leucovorin Calcium
Carboplatin
Letrozole
Fluorouracil
Cisplatin
Atezolizumab

Data sourced from clinicaltrials.gov

Trials

12 of 66
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab
Locations recently updated

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Enrolling
Muscle-invasive Bladder Cancer
Drug: Atezolizumab
Other: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Placebo
Drug: Asundexian (BAY2433334)

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or...

Active, not recruiting
Oropharyngeal Squamous Cell Carcinoma
Drug: Durvalumab
Drug: Tremelimumab

Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it wor...

Active, not recruiting
Lung Cancer Metastatic
Drug: Durvalumab
Drug: Tremelimumab

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Biological: Pembrolizumab

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs pembrolizumab plus maintenance pemetrexed for the treatment of n...

Active, not recruiting
Carcinoma, Non-squamous Non-small-cell Lung
Drug: Carboplatin
Drug: Cisplatin

The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemothe...

Active, not recruiting
Bladder Cancer
Drug: Durvalumab

Trial sponsors

National Cancer Institute (NCI) logo

National Cancer Institute (NCI) (9 trials)

C

Canadian Cancer Trials Group (9 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems